Brexpiprazole Study

Summary

Brexpiprazole Study is a clinical trial^[1].

Key Facts

• Brexpiprazole Study is in the country of United States^[2].
• Brexpiprazole Study's instance of is recorded as clinical trial^[3].
• Brexpiprazole Study's start time is recorded as +2018-03-19T00:00:00Z^[4].
• Brexpiprazole Study's end time is recorded as +2020-03-19T00:00:00Z^[5].
• Brexpiprazole Study's contributor to the creative work or subject is recorded as University of North Carolina at Chapel Hill^[6].
• Brexpiprazole Study's main subject is recorded as schizophrenia^[7].
• Brexpiprazole Study's number of participants is recorded as {'unit': '1', 'amount': '+80'}^[8].
• Brexpiprazole Study's title is recorded as A Multi-center, Randomized, Controlled Trial of Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder^[9].
• Brexpiprazole Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Brexpiprazole Study's ClinicalTrials.gov ID is recorded as NCT03526354^[11].
• Brexpiprazole Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[12].
• Brexpiprazole Study's research intervention is recorded as brexpiprazole^[13].
• Brexpiprazole Study's clinical trial phase is recorded as phase IV clinical trial^[14].
• Brexpiprazole Study's research site is recorded as Massachusetts General Hospital^[15].
• Brexpiprazole Study's research site is recorded as University of Massachusetts^[16].
• Brexpiprazole Study's study type is recorded as interventional study^[17].